U.S. Markets closed

Rigel Pharmaceuticals, Inc. (RIGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.5800+0.1200 (+4.88%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.4600
Open2.4400
Bid2.5100 x 1800
Ask2.5800 x 3100
Day's Range2.3800 - 2.5900
52 Week Range1.2300 - 5.2400
Volume3,276,629
Avg. Volume7,581,770
Market Cap435.837M
Beta (5Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)-0.1490
Earnings DateAug 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.33
  • Benzinga

    Looking Into Rigel Pharmaceuticals's Return On Capital Employed

    Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q2 sales of $16.02 million. Earnings fell to a loss of $17.39 million, resulting in a 182.71% decrease from last quarter. In Q1, Rigel Pharmaceuticals earned $21.03 million, and total sales reached $55.76 million.What Is ROCE? Changes in earnings and sales indicate shifts in Rigel Pharmaceuticals's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed in a business. Generally, a higher ROCE suggests successful growth in a company and is a sign of higher earnings per share for shareholders in the future. In Q2, Rigel Pharmaceuticals posted an ROCE of -0.28%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on RIGLROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Rigel Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will lead to higher returns and earnings per share growth.In Rigel Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q2 Earnings Recap Rigel Pharmaceuticals reported Q2 earnings per share at $-0.10/share, which beat analyst predictions of $-0.13/share.See more from Benzinga * Earnings Scheduled For August 4, 2020 * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session * Morning Market Stats in 5 Minutes(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Rigel Pharmaceuticals Inc (RIGL) Q2 2020 Earnings Call Transcript
    Motley Fool

    Rigel Pharmaceuticals Inc (RIGL) Q2 2020 Earnings Call Transcript

    It is now my pleasure to introduce our first speaker Dolly Vance, who is Rigel's Executive Vice President, Corporate Affairs and General Counsel. As a reminder, during today's call we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory and product development. At this time, I would like to turn the call over to our CEO, Raul Rodriguez.

  • Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

    Rigel (RIGL) delivered earnings and revenue surprises of 23.08% and 12.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?